Above and Below the Belt in Women's Health Care: Cytyc buys Proxima
Executive Summary
Cytyc purchased Proxima Therapeutics, a brachytherapy company with a device to treat breast cancer, for $160 million in cash, following on its acquisition last year of Novacept, a manufacturer of a minimally-invasive endometrial ablation device to treat excessive menstrual bleeding. Three years earlier, Cytyc had acquired Pro-Duct Health, developer of a new test to assess the breast cancer risk of an at-risk patient. Cytyc is clearly going in the direction of creating an overall franchise in women's health, integrating diagnostics and therapeutics, both above and below the belt. But investors want to know that deals don't simply represent a piecemeal, opportunistic approach to business development, but that they fit together in a larger context. It's all about leveraging Cytyc's distribution channel in women's health, says CEO Patrick Sullivan.
You may also be interested in...
Deal Statistics Quarterly, Q1 2005
In this issue, we present another installment of our quarterly review of dealmaking-for January-March 2005. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.
Deal Statistics Quarterly, Q1 2005
In this issue, we present another installment of our quarterly review of dealmaking-for January-March 2005. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.
Schering-Plough, Novartis and Foradil: Measuring the Need for New Products
Schering's willingness to take over the marketing responsibilities for Novartis's Foradil respiratory drug, which has been largely superseded by combination products, to some degree measures the depths of Schering's troubles. But it also indicates the kinds of competition small-company in-licensers are likely to face. A whole industry of in-licensing focused players has grown up to sell the non-core products of Big Pharma: if Schering is any indication, the competition for these products is likely to get even more intense.